To include your compound in the COVID-19 Resource Center, submit it here.

Kyowa discontinues cancer candidate tivantinib

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) said it discontinued development of cancer candidate tivantinib (ARQ 197), saying "positive results were not

Read the full 219 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE